

ESMO Advanced Course on ADC Development, Therapeutic Applications and Research: Thoracic and Genitourinary Cancers

PROGRAMME

**ESMO
ADVANCED COURSE**

**SINGAPORE
9-10 OCTOBER 2024**

Co-Chairs

Ravindran Kanesvaran, Singapore
Solange Peters, Switzerland

ESMO ADVANCED COURSE PROGRAMME

ADC DEVELOPMENT, THERAPEUTIC APPLICATIONS AND RESEARCH: THORACIC AND GENITOURINARY CANCERS

Singapore

9-10 October 2024

CO-CHAIRS Ravindran Kanesvaran, Singapore
Solange Peters, Switzerland

SPEAKERS Aaron R. Hansen, Australia
Nye-Thane Ngo, Singapore
David Planchard, France
Darren M. C. Poon, Hong Kong SAR, China
Egbert F. Smit, The Netherlands
Tira J. Y. Tan, Singapore
Kelvin C. K. Yan, Hong Kong SAR, China

LEARNING OBJECTIVES

- To provide insights on ADCs drug development
- To explain the mechanism of action of the most common ADCs used in clinical practice
- To highlight the integration of ADCs in current clinical practice guidelines across pathologies
- To provide guidance on management of toxicities of ADCs

ACCREDITATION

The programme of this event has been accredited with **8 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano, Switzerland
Email: courses@esmo.org
www.esmo.org



Wednesday, 9 October 2024

09:00-09:10 **Welcome and introduction**

10' Welcome and Learning Objectives
Ravindran Kanesvaran, SG and Solange Peters, CH

09:10-10:40 **Session 1 – ADC Development and pharmacodynamics**

Chair: Ravindran Kanesvaran, SG

20' Mechanisms of action and resistance: ADC internalization and cleavage and mechanisms of resistance
Aaron R. Hansen, AU

20' Toxicity: Prediction, identification and treatment
Tira J. Y. Tan, SG

20' ADC development: What are the considerations in early phase trials?
David Planchard, FR

30' Q&A

10:40-11:10 Coffee break

11:10-11:45 **Session 2 – Target assessment and rationale for combinations**

Chair: Solange Peters, CH

20' Considerations from pathology: Biomarker selection, on-target, off-tumour expression, off-target toxicities
Nye-Thane Ngo, SG

15' Q&A

11:45-12:45 Lunch

12:45-14:15 **Session 3 – Next generation ADCs**

Chair: Ravindran Kanesvaran, SG

20' Developments in ADC constructs including: Bispecific ADCs
Egbert F. Smit, NL

20' Additional innovative strategies: Cytokine conjugates, peptide-based conjugates
Darren M. C. Poon, HK SAR, CN

20' How to develop rationale combinations and sequencing
Kelvin C. K. Yan, HK SAR, CN

30' Q&A

14:15-14:45 Coffee break

19:00 Networking dinner

Thursday, 10 October 2024

09:00-12:30

Workshop sessions

Three parallel workshop sessions with 20 delegates in each group (delegates will attend all 3 sessions on a rotational basis)

15' Introduction based on clinical cases presented by speakers

40' Discussion

5' Break

Workshop 1

ADC trials in GU (bladder cancer)

Ravindran Kanesvaran, SG

Darren M. C. Poon, HK SAR, CN

Workshop 2

ADC trials in thoracic cancers

Solange Peters, CH

Egbert F. Smit, NL

Workshop 3

ADC-related toxicities

Aaron R. Hansen, AU

Tira J. Y. Tan, SG

11:00-11:30

Coffee break

11:30-12:30

Workshops continuation

12:30-13:00

Feedback on the workshops from each group

13:00-13:15

Synthesis and wrap-up

Ravindran Kanesvaran, SG and Solange Peters, CH

13:15-14:15

Lunch